topics / peptide
Tagged peptide.
- Animal only Adipotide (FTPP) A pro-apoptotic peptidomimetic that kills the blood vessels feeding white fat. It produced striking fat loss in obese mice and monkeys, but never cleared safety into meaningful human testing — the lone human trial enrolled four patients and reported no results.
- Preliminary human Amycretin An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere.
- Preliminary human AOD-9604 A growth-hormone fragment marketed for fat loss. The human trials were small and short, the pivotal obesity study failed, and development was abandoned. Unapproved as a drug everywhere.
- Strong human CagriSema An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide.
- Strong human Desmopressin (DDAVP) Desmopressin is an approved synthetic vasopressin analog with strong human evidence for diabetes insipidus and certain bleeding disorders; its biohacking use as a memory enhancer is unsupported and carries a real risk of dangerous low sodium.
- Animal only Dihexa An angiotensin IV-derived oligopeptide studied in animals for synaptogenesis and cognition; it has never been tested in humans, and its foundational mechanism paper was retracted in 2025.
- Preliminary human Ecnoglutide A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved.
- Preliminary human Follistatin 344 A myostatin/activin-pathway antagonist that is biologically real but clinically unproven; its only legitimate human testing was tiny early-phase gene therapy in muscular dystrophy, with no human evidence for muscle-building or weight loss, no regulatory approval, and a permanent WADA ban.
- Preliminary human Glutathione Glutathione is the body's main intracellular antioxidant tripeptide. Oral dosing reliably raises body stores in humans, but the popular IV skin-lightening, anti-aging, and performance claims are unproven — and the injectable cosmetic market carries the real risk.
- Animal only Humanin Humanin is a mitochondrial-derived peptide with interesting cell and animal data in aging and neuroprotection, but the human evidence is entirely observational — no interventional trial of administered humanin in people exists. It's unapproved and effectively uncharacterized for safety in humans.
- Preliminary human Selank A Russian-developed anxiolytic peptide approved in Russia but unproven by Western standards; human trials are small, early, and single-country.
- Preliminary human Semax A Russian-approved nootropic/neuroprotective peptide whose human evidence is real but small, mostly Russian-language, and methodologically thin.
- Preliminary human VIP (Vasoactive Intestinal Peptide) A natural anti-inflammatory neuropeptide with no FDA-approved product; its largest rigorous human trial was negative, and the intranasal 'CIRS' and biohacking uses sold online rest on a single research group's uncontrolled reports.
- Preliminary human VK2735 (Viking) VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown.